What is he best known for?
The fields of study he is best known for:
Epitope, Antigen, Immunology, Molecular biology and Amino acid are his primary areas of study.
The Epitope study which covers Monoclonal antibody that intersects with Endocrinology, Internal medicine, Pinealoma and Immunocytochemistry.
Larry A. Donoso has included themes like Experimental autoimmune encephalomyelitis, Lymphocyte proliferation, Immune system, Ion chromatography and Autoimmune disease in his Antigen study.
His Immunology study frequently involves adjacent topics like Pathology.
His Molecular biology research integrates issues from Pineal gland, Gene expression, Complementary DNA, Fusion protein and Open reading frame.
His Amino acid research is multidisciplinary, incorporating perspectives in Peptide sequence, Conserved sequence and Precipitin.
His most cited work include:
- The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity (564 citations)
- Experimental Allergic Uveitis. Isolation, Characterization, and Localization of a Soluble Uveitopathogenic Antigen from Bovine Retina (468 citations)
- The Role of Inflammation in the Pathogenesis of Age-related Macular Degeneration (426 citations)
What are the main themes of his work throughout his whole career to date?
Larry A. Donoso mainly investigates Pathology, Antigen, Molecular biology, Epitope and Immunology.
His research in Pathology intersects with topics in Retinoblastoma, Eye disease and Melanoma.
Larry A. Donoso combines subjects such as T cell, Immune system, Autoimmune disease, Retinal and Monoclonal antibody with his study of Antigen.
His Molecular biology study also includes
- Peptide and related In vitro,
- Peptide sequence, which have a strong connection to Amino acid.
His Epitope research includes themes of Polyclonal antibodies and Virology.
His work in Retinopathy addresses issues such as Macular degeneration, which are connected to fields such as Gene.
He most often published in these fields:
- Pathology (27.80%)
- Antigen (27.35%)
- Molecular biology (22.42%)
What were the highlights of his more recent work (between 1999-2017)?
- Genetics (13.90%)
- Gene (9.87%)
- Immunology (16.14%)
In recent papers he was focusing on the following fields of study:
Larry A. Donoso spends much of his time researching Genetics, Gene, Immunology, Macular dystrophy and Macular degeneration.
Larry A. Donoso has researched Gene in several fields, including X-linked retinoschisis, Disease, Pathology and Mutation.
His Macular degeneration research incorporates themes from Eye disease, Retinoschisis, Single-nucleotide polymorphism and Retinopathy.
His research in Retinopathy intersects with topics in Retina and RETINOSCHISIN.
His Pathogenesis research integrates issues from H-2 Antigens, Peptide sequence, Molecular biology and Ratón.
His Antigen research is mostly focused on the topic Epitope.
Between 1999 and 2017, his most popular works were:
- The Role of Inflammation in the Pathogenesis of Age-related Macular Degeneration (426 citations)
- Genetic variants near TIMP3 and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration (418 citations)
- Innovations in 3D printing: a 3D overview from optics to organs (362 citations)
In his most recent research, the most cited papers focused on:
His scientific interests lie mostly in Genetics, Immunology, Macular degeneration, Exon and Epitope.
His Macular degeneration study combines topics from a wide range of disciplines, such as Retinopathy, Single-nucleotide polymorphism and Pathogenesis.
The Exon study combines topics in areas such as Osteochondrodysplasia, TBX1, Stickler syndrome and Coding region.
Epitope is a subfield of Antigen that Larry A. Donoso studies.
His biological study spans a wide range of topics, including Lymphocyte proliferation and Uveitis.
Larry A. Donoso interconnects Retina and Maculopathy in the investigation of issues within Ophthalmology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
